Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Takecab

- PMLiVE

Empliciti on track for European approval in multiple myeloma

CHMP backs BMS and AbbVie's therapy after an accelerated assessment

- PMLiVE

Hints of Humira slowdown weigh on AbbVie

Shares decline on Q4 results, but the biologic is still the world's best-selling medicine

- PMLiVE

Merck & Co’s oral hepatitis C therapy approved in US

Fixed-dose combination Zepatier wins a licence from the FDA

- PMLiVE

emotive eye healthcare app scoops mobile learning award

The Eye Education app was produced for Johnson & Johnson Vision Care

- PMLiVE

2015’s ‘premium’ prices dissuaded J&J from acquisitions, says Gorsky

More M&A activity anticipated in 2016 and beyond

- PMLiVE

FDA verdict on Amgen’s Humira biosimilar due in September

Begins review the version of AbbVie's big-selling anti-inflammatory drug

- PMLiVE

Pharma trio join with top universities for new drug search

AZ, GSK and J&J join forces with Imperial, University College and Cambridge

Eli Lilly HQ

Eli Lilly files oral rheumatoid arthritis drug baricitinib in US

Hopes for approval later this year after the drug outperformed Humira in trials

- PMLiVE

Pascale Richetta moves from AbbVie to UCB

She joins the biopharmaceutical company as executive vice president

Roche Basel Switzerland

AbbVie and Roche hoping for speedy venetoclax approval

Leukaemia treatment could reach US and EU markets within months

- PMLiVE

AbbVie takes ‘one-size-fits-all’ HCV regimen into phase III

Comes shortly after Gilead wins priority FDA review for its 'pan-genotypic' treatment

- PMLiVE

ViiV and Janssen plan pivotal trials of monthly HIV treatment

Rilpivirine – cabotegravir combination could provide a monthly option

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links